Binary clinical and regulatory risk - Phase 3 trial failure or FDA rejection would eliminate primary asset value and potentially trigger going concern issues given cash burn rate
Reimbursement pressure from Medicare/Medicaid and private insurers seeking to control specialty pharmaceutical costs, particularly for products without clear superiority to existing therapies
Patent cliff risk - ABC Platform patents and tarcocimab composition of matter patents have finite lives, and biosimilar competition could emerge post-exclusivity
Entrenched competitors with established market share (Regeneron's Eylea franchise $6B+ annually, Roche's Lucentis/faricimab) have physician relationships, reimbursement infrastructure, and brand recognition advantages
Next-generation anti-VEGF therapies in development by larger pharma companies with superior balance sheets and commercial capabilities could leapfrog Kodiak's durability advantages
Port delivery system (Genentech's Susvimo) and gene therapy approaches (Adverum, Regenxbio) represent alternative paradigms that could disrupt injection-based treatment models entirely
Limited cash runway relative to commercialization timeline - with $100M+ annual burn and current ratio of 1.78, the company likely needs additional financing before achieving profitability
High debt/equity ratio of 2.63 creates refinancing risk and potential covenant violations if clinical setbacks occur
Negative ROE of -246% and ROA of -99.7% reflect accumulated losses and capital intensity of drug development - dilution risk from future equity raises is substantial
StructuralCompetitiveBalance Sheet